Nonclinical Development of Multi-targeting Biopharmaceuticals

Abstracts Advances in antibody engineering technologies have resulted in a number of novel biopharmaceutical formats capable of binding to multiple targets. This flexibility provides an opportunity to increase activity, prevent the development of resistance, or introduce unique modes of action that are otherwise not attainable via standard monoclonal antibody formats targeting a single antigen. However, the specific features of these molecules also shape the definition of appropriate nonclinical strategies to support their development. This chapter will review some of the new multi-targeting biopharmaceutical formats, highlight the general challenges and considerations in the nonclinical development of multi-targeting biopharmaceuticals, and provide case study examples of strategies that have been used to develop these novel molecular formats.